Leading brokers name 3 ASX shares to buy today

The ResMed Inc (ASX:RMD) share price is one of three that leading brokers have tipped to climb higher…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Many of Australia's leading brokers are back in the office again after the Christmas break and have been busy adjusting their recommendations to account for new data and developments.

Three shares that have fared well and been given buy ratings are listed below. Here's why they are in favour with brokers:

Pilbara Minerals Ltd (ASX: PLS)

A note out of the Macquarie equities desk reveals that its analysts have retained their outperform rating and $1.20 price target on this lithium miner's shares after its update last week. The broker appears to be pleased that strong demand has led to the company investigating the need for further processing expansions. And although its equity raising is expected to dilute earnings per share, the broker remains positive on Pilbara Minerals due to positive long term demand. While I do like Pilbara Minerals, I intend to see how lithium prices fare in 2019 before considering an investment.

ResApp Health Ltd (ASX: RAP)

According to a note out of Morgans, its analysts have a (high risk) add rating and 24 cents price target on this digital health company's shares. The broker made the move after ResApp announced that it has submitted its CE Mark technical file that is required to allow commercial sales to commence. In addition to this, the broker notes that there are two potential catalysts on the horizon that could move its shares. These are the outcomes of its adult respiratory study in Australia and the clinical adjudication for croup.

ResMed Inc (ASX: RMD)

Analysts at Morgan Stanley have retained their overweight rating and increased the price target on its U.S. shares to US$126 (approximately $17.70 for its ASX listed CDIs). According to the note, the broker has reviewed the healthcare sector ahead of earnings season and sees no reason why ResMed's strong earnings growth trajectory will be disrupted. In light of this, the broker believes that its rich valuation will remain in place for some time to come. I agree with Morgan Stanley on ResMed and think it is one of the best buy and hold options on the local market right now.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

a woman with lots of shopping bags looks upwards towards the sky as if she is pondering something.
Opinions

The pros and cons of buying Zip shares in 2026

There are positive and negative aspects about Zip shares right now…

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Buy, hold, sell: CBA, REA Group, and Xero shares

Morgans has given its verdict on these popular stocks. Let's see if it is bullish on them.

Read more »

A man in a suit looks serious while discussing business dealings with a couple as they sit around a computer at a desk in a bank home lending scenario.
Share Market News

Here's what Westpac says the RBA will do with interest rates in 2026

Stick or twist? Let's see what the RBA could do with rates this year.

Read more »

A woman stretches her arms into the sky as she rises above the crowd.
Best Shares

Fastest rising ASX 200 share of each market sector in 2025

These shares outperformed their sector peers last year.

Read more »

A couple stares at the tv in shock, with the man holding the remote up ready to press a button.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Aristocrat, James Hardie, and TechnologyOne shares

Morgans has given its verdict on these popular shares. Is it bullish, bearish, or something in between?

Read more »

Group of entrepreneurs feeling frustrated during a meeting in the office. Focus is on man with headache.
Share Fallers

5 worst ASX All Ords shares of 2025, and why brokers rate 4 of them a buy

The ASX All Ords rose by 7.11% in 2025 but as always, there were losers in the pack.

Read more »

A female soldier flies a drone using hand-held controls.
Best Shares

These 5 ASX All Ords shares were the fastest risers of 2025

The ASX All Ords rose by 7.11% and delivered total returns, including dividends, of 10.56% in 2025.

Read more »